Figure 6 From: Soluble Fas ligand inhibits angiogenesis in rheumatoid arthritis Effect of soluble Fas ligand (sFasL) on neovascularization in vivo. Matrigel containing vascular endothelial growth factor (VEGF)165 and heparin were injected subcutaneously with or without sFasL (100 ng/ml) into the abdomen of C57BL/6 mice. After 14 days, the mice were sacrificed and the Matrigel plugs were excised and fixed. (a) Representative Matrigel plugs containing PBS (none), VEGF165 (500 ng/ml), or VEGF165 (500 ng/ml) plus sFasL (100 ng/ml). (b) Quantification of new vessel formation via measurements of the hemoglobin (Hb) content within the Matrigel is shown. Eight mice were used for each group. Data represent the mean ± standard deviation, and similar results were obtained with two different experiments. *P < 0.001 versus the Hb content of the Matrigel containing VEGF165. (c) Representative photograph of the gels shown in cross-section and stained with hematoxylin and eosin. Original magnification (×100).Back to article page